申请人:NOVA PHARMACEUTICAL CORPORATION
公开号:EP0242709A2
公开(公告)日:1987-10-28
The invention pertains to novel, potent anticonvulsants, analgesics and cognition enhancers achieving their action through the antagonism of specific excitatory amino acid neurotransmitter receptors. In particular, the invention is directed to ω-[2-phosphonoalkylenyl)phenyl]-2-aminoalkanoic acids having general formula:
Wherein R₁ and R₂ are the same or different and are selected from the group consisting of hydrogen, lower alkyl, halogen, -CH=CH-CH=CH=, amino, nitro, trifluoromethyl or cyano; n and m = 0, 1, 2 or 3; and the pharmaceutically acceptable salts and derivatives thereof.
Examples of specific preferred compounds of general formula are selected from the group consisting of: 4-[2-phosphonomethylphenyl]-2-aminobutanoic acid, ethyl 3-[2-(2- (2-diethylphosphonoethyl)phenyl]-2-acetamido-2-carboethoxypropanoate, 3-[2-phosphonomethyl)phenyl]-2-aminopropanoic acid, ethyl 3-[2-(3-bromopropyl)phenyl]-2-acetamido-3-carboethoxypropanoate, ethyl 3-[2-(3-diethylphosphonopropyl)phenyl]-2-acetamido-2-carboethoxypropanoate, ethyl 3-[2-(3-phosphonopropyl)-phenyl]-2-aminopropanoic acid, ethyl 5-[2-(diethylphosphonomethyl)-phenyl]-2- acetamido-2-carboethoxypentanoate, and 5-[2-phosphonomethylphenyl]-2-aminopentanoic acid. Furthermore, the invention relates to a process for preparing the said potent, selective excitatory amino acid neurotransmitter receptor antagonist.
本发明涉及通过拮抗特定兴奋性氨基酸神经递质受体而发挥作用的新型强效抗惊厥药、镇痛药和认知增强剂。本发明尤其涉及通式为ω-[2-膦酰基烷烯基]苯基]-2-氨基烷酸:
其中,R₁ 和 R₂ 相同或不同,且选自由氢、低级烷基、卤素、-CH=CH-CH=CH=、氨基、硝基、三氟甲基或氰基组成的组;n 和 m = 0、1、2 或 3;及其药学上可接受的盐和衍生物。
具体优选的通式化合物的例子选自以下组成的组:4-[2-膦酰甲基苯基]-2-氨基丁酸、3-[2-(2-二乙基膦酰乙基)苯基]-2-乙酰氨基-2-羧乙氧基丙酸乙酯、3-[2-膦酰甲基)苯基]-2-氨基丙酸、3-[2-(3-溴丙基)苯基]-2-乙酰氨基-3-羧乙氧基丙酸乙酯、3-[2-(3-二乙基膦丙基)苯基]-2-乙酰氨基-2-羧乙氧基丙酸乙酯、3-[2-(3-膦丙基)-苯基]-2-氨基丙酸乙酯、5-[2-(二乙基膦甲基)-苯基]-2-乙酰氨基-2-羧乙氧基戊酸乙酯和 5-[2-膦甲基苯基]-2-氨基戊酸乙酯。此外,本发明还涉及一种制备上述强效、选择性兴奋性氨基酸神经递质受体拮抗剂的工艺。